» Articles » PMID: 28932637

MUC1-C Promotes the Suppressive Immune Microenvironment in Non-small Cell Lung Cancer

Overview
Journal Oncoimmunology
Date 2017 Sep 22
PMID 28932637
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The cancer immune microenvironment is of importance for the effectiveness of immunotherapy; however, its dysregulation is poorly understood. The MUC1-C oncoprotein is aberrantly overexpressed in non-small cell lung cancer (NSCLC) and has been linked to the induction of PD-L1. The present work investigated the effects of targeting MUC1-C in an immuno-competent MUC1 transgenic (MUC1.Tg) mouse model. We show that Lewis Lung Carcinoma cells expressing MUC1-C (LLC/MUC1) exhibit upregulation of PD-L1 and suppression of interferon-γ (IFN-γ). In studies of LLC/MUC1 cells growing and as tumors in MUC1.Tg mice, treatment with the MUC1-C inhibitor, GO-203, was associated with the downregulation of PD-L1 and induction of IFN-γ. The results further demonstrate that targeting MUC1-C results in enhanced effector function of CD8+ tumor-infiltrating lymphocytes (TILs) as evidenced by increased expression of the activation marker CD69, the degranulation marker CD107α, and granzyme B. Notably, targeting MUC1-C was also associated with marked increases in TIL-mediated killing of LLC/MUC1 cells. Analysis of gene expression data sets further showed that overexpression of in NSCLCs correlates negatively with and , and that decreases in and are associated with poor clinical outcomes. These findings in LLC/MUC1 tumors and in NSCLCs indicate that MUC1-C→PD-L1 signaling promotes the suppression of CD8+ T-cell activation and that MUC1-C is a potential target for reprogramming of the tumor microenvironment.

Citing Articles

Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer.

Yang B, Kou R, Wang H, Wang A, Wang L, Sun S Int J Mol Med. 2024; 54(2).

PMID: 38963035 PMC: 11232663. DOI: 10.3892/ijmm.2024.5394.


Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.

Chen T, Wang M, Chen Y, Liu Y Cancer Cell Int. 2024; 24(1):133.

PMID: 38622705 PMC: 11017638. DOI: 10.1186/s12935-024-03315-3.


The Role of MUC1 in Renal Cell Carcinoma.

Milella M, Rutigliano M, Lasorsa F, Ferro M, Bianchi R, Fallara G Biomolecules. 2024; 14(3).

PMID: 38540735 PMC: 10967890. DOI: 10.3390/biom14030315.


MUC1 and MUC16: critical for immune modulation in cancer therapeutics.

Chen X, Sandrine I, Yang M, Tu J, Yuan X Front Immunol. 2024; 15:1356913.

PMID: 38361923 PMC: 10867145. DOI: 10.3389/fimmu.2024.1356913.


Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy.

Zhou Y, Li X, Guo Y, Wu Y, Yin L, Tu L MedComm (2020). 2024; 5(2):e484.

PMID: 38344400 PMC: 10857776. DOI: 10.1002/mco2.484.


References
1.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

2.
Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N . Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016; 55:7-14. DOI: 10.1016/j.ejca.2015.11.020. View

3.
Hasegawa M, Sinha R, Kumar M, Alam M, Yin L, Raina D . Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clin Cancer Res. 2015; 21(10):2338-47. PMC: 4433879. DOI: 10.1158/1078-0432.CCR-14-3000. View

4.
Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N . Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12. PMC: 4672027. DOI: 10.1200/JCO.2014.58.3708. View

5.
Bremnes R, Busund L, Kilvaer T, Andersen S, Richardsen E, Paulsen E . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(6):789-800. DOI: 10.1016/j.jtho.2016.01.015. View